Syngene International Ltd (SYNGENE) — shareholding pattern, promoter holding, financials and share price
About Syngene International Ltd (SYNGENE)
Syngene International Ltd operates in the Healthcare Research, Analytics & Technology industry, within the Healthcare sector. It trades on the NSE as SYNGENE and on the BSE under scrip code 539268. Its ISIN is INE398R01022.
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]
Syngene International Limited is a leading integrated research, development, and manufacturing organization serving sectors like pharmaceuticals, biotechnology, nutrition, and chemicals. Its two main segments, Research Services and Contract Development Manufacturing Services (CDMO), offer a wide range of capabilities across large and small molecules.
The company’s strategic partnerships, particularly its extended relationship with Bristol Myers Squibb, underscore its robust collaborative framework, supporting its scientific and operational expansion until 2035.
Listed peers in Healthcare Research, Analytics & Technology: Indegene Ltd, Suven Life Sciences Ltd, Vimta Labs Ltd, Take Solutions Ltd, Bilcare Ltd, Jeevan Scientific Technology Ltd.
Valuation & Returns
10 Jul 2026At ₹421.9 a share on 10 Jul 2026, Syngene International Ltd (SYNGENE) was valued at a price-to-earnings ratio of 53.78x against an industry P/E of 61.73x and a price-to-book of 3.52x on a book value of ₹119.88 per share as of Mar 2026. Solomo computes return on equity of 6.54% and return on capital employed of 8.68% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 53.78x
- Industry P/E
- 61.73x
- P/B
- 3.52x
- EPS (TTM)
- ₹7.85
- Book value / share
- ₹119.88
- ROE
- 6.54%
- ROCE
- 8.68%
- ROA
- 4.49%
- Debt / equity
- 0.09x
- Dividend yield
- 0.3%
- EBITDA margin
- 24.41%
- 52-week range
- ₹380 – ₹728.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Syngene International Ltd (SYNGENE) reported revenue of ₹3,739 crore, net profit of ₹317 crore and earnings per share of ₹7.86. That compares with revenue of ₹3,642 crore and net profit of ₹496 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,036 crore and net profit ₹148 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2,604 | 3,193 | 3,489 | 3,642 | 3,739 |
| Net profit (₹ cr) | 396 | 464 | 510 | 496 | 317 |
| EPS (₹) | 9.88 | 11.57 | 12.69 | 12.33 | 7.86 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 12.35% | 9.45% | 2.35% | 2.64% |
| Profit growth | 0.66% | -5.46% | -13.62% | -36.17% |
| Stock price CAGR | 7% | -9% | -19% | -37% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.59% of Syngene International Ltd (SYNGENE) (down 0.09 pp QoQ), foreign institutional investors (FII) hold 11.82% and domestic institutional investors (DII) hold 28.02%. Market capitalisation was ₹17,031 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2015.
Largest disclosed public shareholders in Jun 2026: NIPPON LIFE INDIA TRUSTEE LTD- A/C NIPPON INDIA FO 7.73%, ICICI PRUDENTIAL NIFTY SMALLCAP 250 ETF 5.3%, DSP NIFTY SMALLCAP 250 INDEX FUND 4.61%, GOVERNMENT OF SINGAPORE 2.13%, SBI NIFTY SMALLCAP 250 INDEX FUND 1.95%, MIRAE ASSET NIFTY 500 HEALTHCARE ETF 1.85%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.59% | - | 11.82% | 28.02% | 46.98% |
| Mar 2026 | 52.68% | - | 13.9% | 26.44% | 47.03% |
| Dec 2025 | 52.68% | - | 14.96% | 25.84% | 47.02% |
| Sep 2025 | 52.68% | - | 16.31% | 24.62% | 47.01% |
| Jun 2025 | 52.68% | - | 16.5% | 24.05% | 47% |
| Mar 2025 | 52.74% | - | 19.47% | 21.5% | 46.97% |
| Dec 2024 | 52.74% | - | 20.64% | 19.53% | 46.97% |
| Sep 2024 | 54.72% | - | 20.72% | 17.48% | 44.94% |